Aldosterone in heart and kidney diseases

Hellenic Journal of Cardiology

Volumn 46, Issue 6, 2005, Pages 408-419

  Rentoukas, Elias I ^a   Lazaros, Georgios A ^a   Zirogiannis, Panos N ^a,b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Aldosterone; Aldosterone receptor blockers; Cardiovascular diseases; Enalapril; Fibrosis; Osteopontin; Renal disease; TGF

Indexed keywords

ALDOSTERONE; CORTICOTROPIN; EPLERENONE; SPIRONOLACTONE;

ADRENAL CORTEX; ALDOSTERONE RELEASE; CLINICAL TRIAL; GLOMERULUS; GYNECOMASTIA; HEART DISEASE; HEART FAILURE; HUMAN; KIDNEY DISEASE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; POTASSIUM TRANSPORT; REVIEW; SODIUM TRANSPORT; THORAX RADIOGRAPHY;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KIDNEY DISEASES; POTASSIUM; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 30944452795     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Holenberg NK: Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66: 1-9.
2. Seely EW, Williams GH: The heart in endocrine disorders, in Braunwald E, Zipes D, Libby P (eds.): Heart Disease. WB Saunders Company, Philadelphia, 2001: pp 2151-2171.
3. Davis JO: The physiology of congestive heart failure, in Hamilton WF (ed.): Handbook of Physiology, II Circulation, Vol. 3. American Physiological Society, Washington DC, 1965: pp 2071-2122.
4. Funder J: Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 2001; 28: 1002-1006.
5. Takeda R, Hatakeyama H, Takeda Y, et al: Aldosterone biosynthesis and action in vascular cells. Steroids 1995; 60: 120-124.
6. Yu L, Romero DG, Gomez-Sanchez CE, et al: Steroidogenic enzyme gene expression in the human brain. Mol Cell Endocrinol 2002; 190: 9-17.
7. Gomez-Sanchez EP: Central hypertensive effects of aldosterone. Front Neuroendocrinol 1997; 18: 440-462.
8. van Tilborg KA, Rabelink TJ, van Rijn HJ, et al: Arterial baroreflex control of renal hemodynamics in humans. Circulation. 1994; 90: 1883-1890.
9. Wang W, McClain JM, Zucker IH: Aldosterone reduces baroreceptor discharge in the dog. Hypertension 1992; 19: 270-277.
10. Fiebeler A, Schmidt F, Muller DN, et al: Mineralocorticoid receptor affects AP-1 and nuclear factor-kappaB activation in angiotensin II-induced cardiac injury. Hypertension 2001; 37: 787-793.
11. Takeda Y, Yoneda T, Demura M, et al: Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000; 141: 1901-1904.
12. Weber KT: Targeting pathological remodeling: concepts of cardioprotection and reparation. Circulation 2000; 102: 1342-1345.
13. Dluhy RG, Williams GH: Aldosterone - Villain or bystander. N Engl J Med 2004; 351: 8-10.
14. Tobian L: Interrelationship of electrolytes, juxtaglomerular cells and hypertension. Physiol Rev 1960; 40: 280-312.
15. Silva P, Brown RS, Epstein FH: Adaptation to potassium. Kidney Int 1977; 11:466-475.
16. Anker SD, Chua TP, Ponikowski P, et al: Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-534.
17. Kaplan NM: Systemic Hypertension: Therapy, in Braunwald E, Zipes D, Libby P (eds.): Heart Disease. WB Saunders Company, Philadelphia, 2001; pp 972-994.
18. Tsaknakis Th: Aldosterone receptor antagonists in the management of systolic heart failure. Heart Failure 2004; 1: 59-68.
19. Ihara M, Urata H, Kinoshita A, et al: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399-1405.
20. Urata H, Kinoshita A, Misono KS, et al: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
21. Urata H, Healy B, Stewart RW, et al: Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.
22. Tait JF, Little B, Tait SA, et al: Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol Metab 1965; 25: 219-228.
23. Laragh JH: Hormones and the pathogenesis of congestive heart failure: vasopressin, aldosterone, and angiotensin II. Further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis. Circulation 1962; 25: 1015-1023.
24. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697.
25. Moe GW, Legault L, Skorecki KL: Control of extracellular fluid volume and pathophysiology of edema formation, in Brenner, BM and Rector FC Jr (eds.): The Kidney, 4th ed. W B Saunders Company, Philadelphia, 1991: pp 623-676.
26. Mortensen RM, Williams GH: Aldosterone action: Physiology, in DeGroot LJ, et al. (eds.): Endocrinology, Vol. 1, 3rd ed. WB Saunders Company, Philadelphia, 1995; 1668-1975.
27. La Villa G, Stefani L, Lazzeri C, et al: Acute effects of physiological increments of brain natriuretic peptide in humans. Hypertension 1995; 26: 628-633.
28. Goldhaber SZ: Pulmonary embolism, in Braunwald E, Zipes D, Libby P (eds.): Heart Disease. WB Saunders Company, Philadelphia, 2001: pp 1886-1907.
29. Oster JR, Singer I, Fishman LM: Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995; 98: 575-586.
30. Covit AB, Schaer GL, Sealey JE, et al: Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med 1983; 75: 445-447.
31. van Veldhuisen DJ, Brouwer J, Man in 't Veld AJ, et al: Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. DIMT Study Group. Dutch Ibopamine Multicenter Trial. Am J Cardiol 1995; 75: 796-800.
32. Cappuccio FP, Markandu ND, Sagnella GA, et al: The effect of oral digoxin on sodium excretion, renin-angiotensin-aldosterone system and blood pressure in normotensive subjects. Postgrad Med J 1986; 62: 265-268.
33. Verrey F: Early aldosterone effects. Exp Nephrol 1998; 6: 294-301.
34. Losel RM, Falkenstein E, Feuring M, et al: Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 2003; 83: 965-1016.
35. Barbato JC, Mulrow PJ, Shapiro JL, et al: Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension 2002; 40: 30-135.
36. Wehling M, Spes H, Win N, et al: Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522.
37. Wehling M: Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 1997; 59: 365-393.
38. Rocha R, Rudolph AE, Frierdich GE, et al: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002; 283: H1802-H1810.
39. Rocha R, Funder JW: The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002; 970: 89-100.
40. Chander PN, Rocha R, Ranaudo J, et al: Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. Am Soc Nephrol 2003; 14: 1990-1997.
41. Rocha R, Martin-Berger CL, Yang P, et al: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143:4828-4836.
42. Rudolph AE, Rocha R, McMahon EG: Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol 2004; 217: 229-238.
43. Qin W, Rudolph AE, Bond BR, et al: Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69-76.
44. Stier CT Jr, Chander PN, Rocha R: Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10: 97-107.
45. Rocha R, Stier CT Jr, Kifor I, et al: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878.
46. Rocha R, Chander PN, Zuckerman A, et al: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237.
47. Duprez DA, De Buyzere ML, Rietzschel ER, et al: Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.
48. Duprez DA, Bauwens FR, De Buyzere ML, et al: Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993; 71: 17A-20A
49. Sugihara N, Genda A, Shimizu M, et al: Diastolic dysfunction and its relation to myocardial fibrosis in essential hypertension. J Cardiol 1988; 18: 353-361.
50. Weber KT, Villarreal D: Role of aldosterone in congestive heart failure. Postgrad Med 1993; 93: 203-207.
51. Brilla CG: Aldosterone and myocardial fibrosis in heart failure. Heart 2000; 25: 299-306.
52. Brilla CG, Matsubara LS, Weber KT: Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A
53. Sokol SI, Portnay EL, Curtis JP, et al: Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004; 63: 208-213.
54. 2 in peripheral blood mononuclear cells. Circulation 2005; 111: 51-57.
55. Hostetter TH, Ibrahim HN: Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 2003; 14: 2395-2401.
56. Silvestre JS, Robert V, Heymes C, et al: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998; 273:4883-4891.
57. Delcayre C, Silvestre JS, Garnier A, et al: Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000; 57: 1346-1351.
58. Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-677.
59. Zhou MY, Gomez Sanchez CE, Gomez Sanchez EP: An alternatively spliced rat mineralocorticoid receptor mRNA causing truncation of the steroid binding domain. Mol Cell Endocrinol 2000; 159: 125-131.
60. Delyani JA: Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000; 57: 1408-1411.
61. Hollenberg NK: Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66: 1-9.
62. Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269: E657-662.
63. Brilla CG, Matsubara LS, Weber KT: Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A
64. Duprez DA, De Buyzere ML, De Backer T, et al: Influence of systemic arterial blood pressure and nonhemodynamic factors on the brachial artery pulsatility index in mild to moderate essential hypertension. Am J Cardiol 1993; 71: 350-353.
65. Duprez DA, Bauwens FR, De Buyzere ML, et al: Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1996; 71: 17A-20A
66. Djau VJ, Colluci WS, Holenberg NK, et al: Relation of reninangiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-651.
67. Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996; 2: 855-860.
68. Weber KT: Aldosterone and spironolactone in heart failure. N Engl J Med 1999; 341: 753-755.
69. Okubo S, Niimura F, Nishimura H, et al: Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997; 99: 855-860.
70. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized ALdactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
71. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-acute myocardial infarction Heart failure Efficacy and SUrvival Study investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
72. Zannad F, Alla F, Dousset B, et al, on behalf of the RALES Investigators: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000; 102: 2700-2706.
73. Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215-262.
74. Korantzopoulos P, Kolettis Th, Kountouris E, et al: Atrial remodeling in persistent atrial fibrillation. The potential role of aldosterone. Eur Heart J 2004; 25: 1086.
75. Farquharson CAJ, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-601.
76. Jessup M: Aldosterone blockade and heart failure. N Engl J Med 2003; 348: 1380-1382.
77. Hunt SA, Baker DW, Chin MH, et al: American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001; 104: 2996-3007.
78. de Gasparo M, Joss U, Ramjoue HP, et al: Three new epoxyspirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650-656.
79. Pitt B: Aldosterone blockade in patients with acute myocardial infarction. Circulation 2003; 107: 2525-2527.
80. Hayashi M, Tsutamoto T, Wada A, et al: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003; 107: 2559-2565.
81. Delyani JA, Robinson EL, Rudolph AE: Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001; 281: H647-H654.
82. Ward MR, Kanellakis P, Ramsey D, et al: Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001; 104: 467-472.
83. MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30-34.
84. Yee KM, Pringle SD, Struthers AD: Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001; 37:1800-1807.
85. Wang W: Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24: 571-575.
86. Miller JM, Zipes DP: Management of the patients with cardiac arrhythmias, in Braunwald E, Zipes D, Libby P (eds.): Heart Disease. WB Saunders Company, Philadelphia, 2001; pp 700-774.
87. DeFerrari GM, Vanoli E, Schwartz PJ: Cardiac vagal activity, myocardial ischemia, and sudden death, in Zipes DP, Jalife J (eds.): Cardiac Electrophysiology: From Cell to Bedside, 2nd ed. WB Saunders Company, Philadelphia, 1994; pp 422-438.
88. Green El, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068.
89. Conn JW: Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.
90. Conn JW: Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome, 1954. J Lab Clin Med 1990; 116: 253-267.
91. Weber KT, Brilla CG: Myocardial fibrosis and the renin-angiotensin- aldosterone system. J Cardiovasc Pharmacol 1992; 20 (Suppl 1): S48-54.
92. Fullerton MJ, Funder JW: Aldosterone and cardiac fibrosis: In vitro studies. Cardiovasc Res 1994; 28: 1863-1867.
93. Zhou X, Ono H, Ono Y, et al: Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004; 24: 242-249.
94. Nishiyama A, Yao L, Nagai Y, et al: Possible contributions of reactive oxygen species, mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43: 841-848.
95. Blasi ER, Rocha R, Rudolph AE, et al: Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800.
96. Brown NJ, Nakamura S, Ma L, et al: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227.
97. Juknevicius I, Segal Y, Kren S, et al: Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal 2004; 286: F1059- F1062.
98. Ma LJ, Yang H, Gaspert A, et al: Transforming growth factor-beta- dependent and independent pathways of induction of tubulointerstitial fibrosis in beta6 (-/-) mice. Am J Pathol 2003; 163: 1261-1273.
99. Hostetter TH, Ibrahim HN: Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 2003; 14: 2395-2401.
100. Hostetter TH, Rosenberg ME, Ibrahim HN, et al: Aldosterone in progressive renal disease. Semin Nephrol 2001; 21: 573-579.
101. Reams GP, Bauer JH: Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med 1986; 146: 2145-2148.
102. Daniels BS, Hostetter TH: Effects of dietary protein intake on vasoactive hormones. Am J Physiol 1990; 258: R1095-R1100.
103. Correa-Rotter R Hostetter TH, Manivel JC, Rosenberg ME: Renin expression in renal ablation. Hypertension 1992; 20: 483-490.
104. Rosenberg ME, Swanson JE, Thomas BL, Hostetter TH: Glomerular and hormone responses to dietary protein intake in human renal disease. Am J Physiol 1987; 253: F1083-F1090.
105. Salahudeen AK, Hostetter TH, Raatz SK, Rosenberg ME: Effects of dietary protein in patients with chronic renal transplant rejection. Kidney Int 1992; 41: 183-190.
106. Epstein M: Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. Am J Kidney Dis 2001; 37: 677-688.
107. Hene RJ, Boer P, Koomans HA, et al: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101.
108. Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW: Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978; 14: 228-235.
109. Walker WG: Hypertension related injury: A major contributor to end-stage renal disease. Am J Kidney Dis 1993; 22: 164-173.
110. Ciraku I, Kailasam M, O'Conner D, Parmer R: Renal aldosterone excretion predicts early renal injury in human essential hypertension. J Am Soc Nephrol 2000; 11: 345 (abstract).
111. Quan ZY, Walser M, Hill GS: Adrenalectomy ameliorates ablative nefropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41: 326-333.
112. Chrysostomou A, Becker G: Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926.
113. Sato A, Hayashi K, Naruse M, et al: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
114. Pitt B, Reichek N, Willenbrock R, et al: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.
115. Williams GH, Burgess E, Kolloch RE, et al: Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93: 990-996.
116. White WB, Duprez D, St Hillaire R, et al: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026.
117. Horiuchi M, Nishiyama H, Hama J, et al: Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol 1993; 264: F286-F291.
118. Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.